e8vk
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2006
QUESTCOR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
California
(State or Other Jurisdiction
of Incorporation)
|
|
001-14758
(Commission File Number)
|
|
33-0476164
(I.R.S. Employer Identification No.) |
|
|
|
3260 Whipple Road, Union City, California
(Address of Principal Executive Offices)
|
|
94587
(Zip Code) |
Registrants telephone number, including area code: (510) 400-0700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)) |
This Current Report on Form 8-K is furnished by Questcor Pharmaceuticals, Inc., a California
corporation (the Company), in connection with the matters described herein.
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer
of Listing.
On January 9, 2006, as described in Item 5.02 below, the Company received notice that Howard
D. Palefsky was resigning as a director of the Company effective immediately as of that date. At
the time of his resignation Mr. Palefsky served on the Companys audit committee. On
January 10, 2006, the Companys Board of Directors unanimously approved the appointment of Virgil
D. Thompson, a current independent director of the Company, to the Companys audit committee to
fill the vacancy created by Mr. Palefskys resignation.
On January 9, 2006, as a result of Mr. Palefskys resignation, the Company had only two
independent directors on its audit committee. Accordingly, the Company notified the American Stock
Exchange (AMEX) that it was not in compliance on that date with Section 121 of the AMEX Company
Guide, which requires that audit committees be composed of at least three independent directors. As
a result of the appointment of Virgil D. Thompson to the audit committee on January 10, 2006, the
Company is now in compliance with Section 121 of the AMEX Company Guide.
Item 5.02. Departure of Directors or Principal Officers, Election of Directors; Appointment of
Principal Officers.
On January 9, 2006, the Company received notice that Howard D. Palefsky was resigning as a
director of the Company effective immediately as of that date. At the time of his resignation Mr.
Palefsky served on the Companys audit committee.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: January 12, 2006 |
QUESTCOR PHARMACEUTICALS, INC.
|
|
|
By: |
/s/ JAMES L. FARES
|
|
|
|
James L. Fares |
|
|
|
President and Chief Executive Officer |
|
|